Any of the following cardiac conditions:\r\n* Documented New York Heart Association (NYHA) class III or IV congestive heart failure\r\n* Myocardial infarction within  months prior to randomization\r\n* Unstable angina within  months prior to randomization\r\n* Symptomatic arrhythmia
Have the presence of cardiac disease, including a myocardial infarction within  months prior to study entry, unstable angina pectoris, New York Heart Association Class III/IV congestive heart failure, or uncontrolled hypertension.
Patients with active heart disease (New York Heart Association [NYHA] class - as assessed by history and physical examination, unstable angina/stroke/myocardial infarction within the last  months)
Active angina or Class III or IV Congestive Heart Failure (New York Heart Association CHF Functional Classification System) or clinically significant cardiac disease within  months of the first dose of study drug, including myocardial infarction, unstable angina, Grade  or greater peripheral vascular disease, congestive heart failure, uncontrolled hypertension, or arrhythmias not controlled by medication
Congestive heart failure (CHF) New York (NY) Heart Association class III or IV; unstable coronary artery disease (myocardial infarction [MI] more than  months prior to study entry is permitted); or serious cardiac arrhythmia
Congestive heart failure (New York Heart Association Class III or IV), myocardial infarction within  months before starting study treatment, or unstable or poorly controlled angina pectoris, including Prinzmetal variant angina pectoris.
Congestive heart failure (New York Heart Association Class III or IV) or unstable angina pectoris. Previous history of myocardial infarction within  year prior to study entry, uncontrolled hypertension or uncontrolled arrhythmias
Active angina pectoris or NY Heart Association Class III-IV
History of unstable or deteriorating cardiac disease within the previous  months prior to screening including but not limited to the following:\r\n* Unstable angina or myocardial infarction\r\n* Congestive heart failure (New York Heart Association [NYHA] class III or IV)\r\n* Uncontrolled clinically significant arrhythmias.
Active cardiac disease defined as symptomatic congestive heart failure, history of New York Heart Association (NYHA) class III or IV heart failure, uncontrollable supraventricular arrhythmias, any history of a ventricular arrhythmia, active angina pectoris, myocardial infarction or coronary intervention within  months of registration
Congestive heart failure (New York Heart Association Class III or IV), myocardial infarction within  months before starting study treatment, or unstable or poorly controlled angina pectoris, including Prinzmetal variant angina pectoris.
Patients with a serious cardiac condition, such as congestive heart failure; New York Heart Association class III/IV heart disease; unstable angina pectoris; myocardial infarction within the last  months; valvulopathy that is severe, moderate, or deemed clinically significant despite medical intervention; or arrhythmias that are symptomatic or refractory to medical intervention
Evidence of current uncontrolled cardiovascular conditions (New York Heart Association [NYHA] class III or IV), including hypertension, cardiac arrhythmias, congestive heart failure, unstable angina, or myocardial infarction within the past  months; Note: prior to study entry, any electrocardiogram (ECG) abnormality at screening must be documented by the investigator as not medically relevant
Cardiovascular disease that meets one of the following: congestive heart failure (New York Heart Association class III or IV), active angina pectoris, or recent myocardial infarction (within the last  months)
Congestive heart failure (New York Heart Association class III or IV), myocardial infarction within  months before starting study treatment, or unstable or poorly controlled angina pectoris, including Prinzmetal variant angina pectoris
Clinically significant cardiac illness including New York Heart Association (NYHA) class III or class IV heart failure, unstable angina pectoris, myocardial infarction within the past  months, or >= grade  cardiac arrhythmias noted =<  days prior to registration
Congestive heart failure (New York Heart Association Class III or IV) or unstable angina pectoris. Previous history of myocardial infarction within  year prior to study entry, uncontrolled hypertension or uncontrolled arrhythmias
Significant active cardiac disease within  months prior to the start of study treatment, including New York Heart Association (NYHA) Class III or IV congestive heart failure; myocardial infarction, unstable angina and/or stroke; or LVEF <% by echocardiogram (ECHO), or by other methods according to institutional practice, obtained within  days prior to the start of study treatment
Has known cardiopulmonary disease defined as unstable angina, clinically significant arrhythmia, congestive heart failure (New York Heart Association Class III or IV), and/or myocardial infarction within  months before first dose, or severe pulmonary hypertension.
Presence of cardiac impairment defined as:\r\n* Prior history of cardiovascular disease including heart failure that meets New York Heart Association (NYHA) class III and IV definitions; OR \r\n* History of myocardial infarction/active ischemic heart disease within one year of study entry; OR \r\n* Uncontrolled dysrhythmias; OR \r\n* Poorly controlled angina
Has the any of the following cardiac history:\r\n* Active heart disease including myocardial infarction within previous  months\r\n* Symptomatic coronary artery disease\r\n* Arrhythmias not controlled by medication\r\n* Unstable angina pectoris\r\n* Uncontrolled or symptomatic congestive heart failure (New York Heart Association [NYHA] class III and IV)
Has active angina or Class III or IV Congestive Heart Failure (New York Heart Association CHF Functional Classification System) or clinically significant cardiac disease within  months of randomization, including myocardial infarction, unstable angina, Grade  or greater peripheral vascular disease, congestive heart failure, or arrhythmias not controlled by medication.
Clinically significant cardiac illness including New York Heart Association (NYHA) class III or class IV heart failure, unstable angina pectoris, myocardial infarction within the past  months, or >= grade  cardiac arrhythmias noted =<  days prior to registration
Clinically significant heart disease, including the following:\r\n* Active severe angina pectoris prior to registration\r\n* Acute myocardial infarction prior to registration\r\n* New York Heart Association classification IV cardiovascular disease or symptomatic class III disease\r\n* Note: patients with any of the above may be allowed after discussion amongst the investigators including the principal investigator
Patients with a history of unstable or newly diagnosed angina pectoris, recent myocardial infarction (within  months of enrollment) or New York Heart Association class IIIV congestive heart failure
Significant active cardiac disease within the previous  months including: New York Heart Association (NYHA) class  congestive heart failure (CHF), unstable angina, myocardial infarction
Subjects with a history of a cardiovascular illness including: congestive heart failure (New York Heart Association grade III or IV); unstable angina or myocardial infarction within the previous  months; or symptomatic cardiac arrhythmia despite medical management
Patients who have significant cardiac disease, including but not limited to history of congestive heart failure (New York Heart Association Class III/IV; see Appendix ), unstable angina, or uncontrolled cardiac arrhythmia.
Have the presence of cardiac disease, including a myocardial infarction within  months prior to study entry, unstable angina pectoris, New York Heart Association Class III/IV congestive heart failure, or uncontrolled hypertension.
History of New York Heart Association class - congestive heart failure or patients with history myocardial infarction within  months of starting study treatment
Significant active cardiac disease within the previous  months, including: New York Heart Association (NYHA) class III or IV congestive heart failure; unstable angina or angina requiring surgical or medical intervention, and/or; myocardial infarction
Clinically significant heart disease, including the following:\r\n* Active severe angina pectoris within  months prior to registration\r\n* Acute myocardial infarction within  months prior to registration\r\n* New York Heart Association classification IV cardiovascular disease or symptomatic class III disease\r\n** Note: patients with any of the above may be allowed after discussion amongst the investigators including the principal investigator
Clinically significant heart disease (eg, congestive heart failure of New York Heart Association Class  or  angina, not well controlled by medication, or myocardial infarction within  months)
Serious medical illness, such as significant cardiac disease (e.g. symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within the past  months, uncontrolled cardiac arrhythmia, pericardial disease or New York Heart Association class III or IV), or severe debilitating pulmonary disease, that would potentially increase patients risk for toxicity
Patients with active heart disease (New York Heart Association [NYHA] class - as assessed by history and physical examination, unstable angina/stroke/myocardial infarction within the last  months)
Active heart disease including myocardial infarction within previous  months, symptomatic coronary artery disease, arrhythmias not controlled by medication, or uncontrolled congestive heart failure (New York Heart Association class III and IV)
Clinically significant cardiac disease, including major cardiac dysfunction, such as uncontrolled angina, clinical congestive heart failure with New York Heart Association (NYHA) class III or IV, ventricular arrhythmias requiring anti-arrhythmic therapy, recent (within  months) myocardial infarction or unstable coronary artery disease
Cardiac dysfunction defined as myocardial infarction within  months of study entry, New York Heart Association Class III or IV heart failure, uncontrolled dysrhythmias or poorly controlled angina.
Patients with pre-existing cardiovascular disease requiring ongoing treatment; this includes: a) congestive heart failure class III/IV congestive heart failure (CHF) per New York Heart Association (NYHA) criteria; b) cardiomyopathy; c) uncontrolled cardiac arrhythmia; d) unstable angina pectoris; e) recent myocardial infarction (MI) (within  months)
No significant cardiac disease, including the following: unstable angina, New York Heart Association class II-IV congestive heart failure, myocardial infarction within six months prior to study enrollment
Patients with clinically significant cardiovascular co-morbidities including: congestive heart failure (New York Heart Association class III-IV heart disease), unstable angina pectoris, cardiac arrhythmias requiring medication or a pacemaker; myocardial infarction within the past six months; stroke within the past  months; or hypertension requiring more than  medications for blood pressure control.
Serious medical illness, such as significant cardiac disease (e.g. symptomatic congestive heart failure, unstable angina pectoris, coronary artery disease, myocardial infarction within the past  months, uncontrolled cardiac arrhythmia, pericardial disease or New York Heart Association class III or IV), or severe debilitating pulmonary disease, that would potentially increase patients risk for toxicity
Patients with pre-existing cardiovascular disease requiring ongoing treatment; this includes: congestive heart failure III/IV as defined by New York Heart Association (NYHA); uncontrolled cardiac arrhythmia; unstable angina pectoris; and recent myocardial infarction (MI) (within  months)
Significant cardiac disease including heart failure that meets New York Heart Association (NYHA) class III and IV definitions; history of myocardial infarction within one year of study entry; uncontrolled dysrhythmias; or poorly controlled angina.
Subject has any one of the following:\r\n* Clinically significant abnormal electrocardiogram (ECG) finding at screening\r\n* Congestive heart failure (New York Heart Association class III or IV)\r\n* Myocardial infarction within  months prior to starting study treatment\r\n* Unstable or poorly controlled angina pectoris, including Prinzmetal variant angina pectoris
Patients with cardiovascular (CV) disease conditions including New York Heart Association class  or  congestive heart failure, unstable angina pectoris, or clinically important cardiac arrhythmias OR a recent (<  months) CV event, including myocardial infarction, unstable angina pectoris, or stroke.
Active angina or Class III or IV Congestive Heart Failure (New York Heart Association CHF Functional Classification System) or clinically significant cardiac disease within  months of the first dose of study drug, including myocardial infarction, unstable angina, Grade  or greater peripheral vascular disease, congestive heart failure, uncontrolled hypertension, or arrhythmias not controlled by medication
Myocardial infarction within the last  months, severe/unstable angina, symptomatic congestive heart failure New York Heart Association (NYHA) class III or IV
Cardiovascular disease that meets one of the following: congestive heart failure (New York Heart Association class III or IV), active angina pectoris, or recent myocardial infarction (within the last  months)
Cardiovascular disease that meets one of the following: congestive heart failure (New York Heart Association class III or IV), active angina pectoris, or recent myocardial infarction (within the last  months)
Cardiovascular disease that meets one of the following: congestive heart failure (New York Heart Association class III or IV), active angina pectoris, or recent myocardial infarction (within the last  months)
Cardiovascular disease that meets one of the following: congestive heart failure (New York Heart Association class III or IV), active angina pectoris, or recent myocardial infarction or acute coronary syndrome (within the last  months)
Patients must not have clinically significant illness including uncontrolled, active infection requiring intravenous antibiotics, New York Heart Association (NYHA) class III or class IV heart failure, unstable angina pectoris, myocardial infarction within the past  months, or >= grade  cardiac arrhythmias
Serious medical illness, such as significant cardiac disease (e.g. symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within the past  months, uncontrolled cardiac arrhythmia, pericardial disease or New York Heart Association class III or IV), or severe debilitating pulmonary disease, that would potentially increase patients risk for toxicity
Patients must not have New York Heart Association class III or IV heart failure at the time of screening; patients must not have any thromboembolic event, unstable angina pectoris, myocardial infarction, or serious uncontrolled cardiac arrhythmia within  months prior to registration (Note: Patients with congenital long AT syndrome, congestive heart failure, frequent electrolyte abnormalities, and patients taking drugs known to prolong the QT interval may be at increased risk)
Clinically significant or uncontrolled cardiac disease including unstable angina, acute myocardial infarction within  months from Day  of study drug administration, New York Heart Association Class III or IV congestive heart failure, circulatory collapse requiring vasopressor or inotropic support, or arrhythmia that requires therapy.
For Cohort A: Has symptomatic congestive heart failure (New York Heart Association Class III or IV heart disease), unstable angina pectoris, cardiac arrhythmia, or uncontrolled hypertension
Cardiovascular disease that meets one of the following: congestive heart failure (New York Heart Association class III or IV), active angina pectoris, or recent myocardial infarction (within the last  months)
History of myocardial infarction and unstable angina within  months before study drug treatment; symptomatic congestive heart failure (Congestive Heart Failure New York Heart Association Class III or IV); congenital long QT syndrome; or ventricular arrhythmias defined as grade ? according to NCI CTCAE, v
Active angina or Class III or IV Congestive Heart Failure (CHF) (New York Heart Association CHF Functional Classification System) or clinically significant cardiac disease within  months of study enrollment, including myocardial infarction, unstable angina, grade  or greater peripheral vascular disease, congestive heart failure, uncontrolled hypertension, or arrhythmias not controlled by outpatient medication
Other uncontrolled illness or medical condition, such as active infection, symptomatic heart failure (New York Heart Association class III or IV; moderate to severe objective evidence of cardiovascular disease), unstable angina pectoris, myocardial infarction or stroke within last  months, psychiatric illness that may limit compliance with study requirement or interfere with the understanding and giving of informed consent;
Significant cardiac disease, including the following: unstable angina, New York Heart Association class II-IV congestive heart failure, myocardial infarction within six months prior to study enrollment.
Clinically significant heart disease (eg, congestive heart failure of New York Heart Association Class  or , angina not well controlled by medication, or myocardial infarction within  months)
Active grade III-IV cardiac failure as defined by the New York Heart Association criteria, uncontrolled angina or myocardial infarction (MI) within  months
Myocardial infarction within the last  months, severe/unstable angina, symptomatic congestive heart failure, New York Heart Association (NYHA) class III or IV
have the presence of cardiac disease, including a myocardial infarction within  months prior to study entry, unstable angina pectoris, New York Heart Association Class III/IV congestive heart failure, or uncontrolled hypertension.
Cardiovascular disease that meets one of the following: congestive heart failure (New York Heart Association class III or IV), active angina pectoris, or recent myocardial infarction (within the last  months)
Patient has clinically significant heart disease (such as uncontrolled angina, myocardial infarction within the last  months or congestive heart failure of New York Heart Association III or IV)
Patients who have any severe and/or uncontrolled cardiac disease within =<  months prior to start of everolimus, including: unstable angina pectoris, symptomatic congestive heart failure of New York Heart Association class III or IV, myocardial infarction, serious uncontrolled cardiac arrhythmia, or any other clinically significant cardiac disease
Active angina or Class III or IV Congestive Heart Failure (CHF) (New York Heart Association CHF Functional Classification System) or clinically significant cardiac disease within  months of the first dose of study drug, including myocardial infarction, unstable angina, Grade  or greater peripheral vascular disease, congestive heart failure, uncontrolled hypertension, or arrhythmias not controlled by outpatient medication
Patients with a history of unstable or newly diagnosed angina pectoris, recent myocardial infarction (within  months of enrollment) or New York Heart Association class IIIV congestive heart failure
Patients with clinically significant cardiovascular disease: \r\n* History of cerebrovascular accident (CVA) within  months \r\n* Myocardial infarction or unstable angina within  months \r\n* Unstable angina pectoris\r\n* New York Heart Association class III or greater congestive heart failure
Any history of unstable angina, myocardial infarction, New York Heart Association (NYHA) class III or IV heart failure, and/or pulmonary hypertension
Significant cardiovascular disease including congestive heart failure (New York Heart Association class II or higher) or active angina pectoris
Cardiovascular disease that meets one of the following: congestive heart failure (New York Heart Association Class III or IV), active angina pectoris, or recent myocardial infarction (within the last  months).
Significant cardiovascular disease defined as congestive heart failure (New York Heart Association class III or IV cardiac disease), angina pectoris requiring nitrate therapy or recent myocardial infarction (=<  months prior to registration)
Active heart disease including myocardial infarction within previous  months, symptomatic coronary artery disease, clinically significant arrhythmias not controlled by medication, atrial fibrillation (whether active or known past history), uncontrolled angina, or uncontrolled congestive heart failure (New York Heart Association Class III or IV).
History of myocardial infarction or other evidence of arterial thrombotic disease (angina), symptomatic congestive heart failure (New York Heart Association >= grade ), unstable angina pectoris, or cardiac arrhythmia; Note: allowed only if patient has no evidence of active disease for at least  months prior to randomization
Have the presence of cardiac disease, including a myocardial infarction within  months prior to study entry, unstable angina pectoris, New York Heart Association (NYHA) Class III/IV congestive heart failure, or uncontrolled hypertension
The patient has a serious cardiac condition, such as congestive heart failure; New York Heart Association class II/ III/IV heart disease; unstable angina pectoris, cardiac stenting within  months of enrollment; myocardial infarction within the last  months; valvulopathy that is severe, moderate, or deemed clinically significant; or arrhythmias that are symptomatic or require treatment
Clinically significant cardiac disease including unstable angina, acute myocardial infarction within  months from day  of study administration, New York Heart Association class III or IV congestive heart failure, or symptomatic uncontrolled arrhythmias, prolonged corrected QT interval >  msec, treatment refractory hypertension, presence of a cardiac defibrillator
Patients with clinically significant cardiovascular disease: myocardial infarction or unstable angina pectoris within the last  months, class III/IV New York Heart Association (NYHA) heart failure
Documented myocardial infarction or unstable/uncontrolled cardiac disease (eg, unstable angina, congestive heart failure [New York Heart Association > Class III]) within  months or enrollment
No uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure (New York Heart Association [NYHA] class III or IV), unstable angina pectoris or new onset angina that began within the last  months, cardiac ventricular arrhythmias requiring anti-arrhythmic therapy
Unstable angina, myocardial infarction or New York Heart Association (NYHA) class III/IV congestive heart failure within  days preceding study enrollment
Clinically significant cardiac disease including unstable angina, acute myocardial infarction within  months from Day  of study drug administration, New York Heart Association Class II, III, or IV congestive heart failure, and arrhythmia requiring therapy.
Any of the following cardiovascular conditions or values within  months before the first dose of study drug: myocardial infarction and the New York Heart Association (NYHA) class III or IV heart failure
Clinically significant cardiac disease including unstable angina, acute myocardial infarction within six months prior to randomization, congestive heart failure (New York Heart Association [NYHA] III-IV), and uncontrolled symptomatic arrhythmia
Patients with significant cardiovascular disease including congestive heart failure (New York Heart Association [NYHA] class III or IV), active angina pectoris or myocardial infarction within  months
Have a serious cardiac condition, such as congestive heart failure; New York Heart Association Class III/IV heart disease; unstable angina pectoris; myocardial infarction within the last  months; valvulopathy that is severe, moderate, or deemed clinically significant; or arrhythmias that are symptomatic or require treatment (not including participants with rate-controlled atrial fibrillation).
Congestive heart failure (New York Heart Association Class III or IV), myocardial infarction within  months before starting study treatment, or unstable or poorly controlled angina pectoris, including Prinzmetal variant angina pectoris.
Presence of cardiac impairment defined as:\r\n* Prior history of cardiovascular disease including heart failure that meets New York Health Association (NYHA) class III and IV definitions; OR \r\n* History of myocardial infarction/active ischemic heart disease within one year of study entry; OR \r\n* Uncontrolled dysrhythmias; OR \r\n* Poorly controlled angina
Significant cardiovascular disease (such as New York Heart Association Class III or IV cardiac disease, congestive heart failure, myocardial infarction within the previous  months, unstable arrhythmias, or unstable angina) or significant pulmonary disease (including obstructive pulmonary disease and history of bronchospasm)
Clinically significant cardiac disease including unstable angina, acute myocardial infarction within  months from day  of study drug administration, New York Heart Association class III or IV congestive heart failure, or symptomatic arrhythmias requiring therapy
Recent history (within  months of start of screening) of unstable angina pectoris pattern, myocardial infarction (including non-Q wave MI), or NYHA (New York Heart Association) Class III and IV Congestive Heart Failure (CHF)
Any severe concurrent disease or condition (including severe graft-versus-host disease, requirement for dialysis, symptomatic congestive heart failure [New York Heart Association Class III or IV], unstable angina pectoris, cardiac arrhythmia) which, in the judgment of the Investigator, would make the patient inappropriate for study participation.
Uncontrolled hypertension, heart disease including history of congestive heart failure, history of myocardial infarction, angina pectoris requiring medication, clinically significant valvular heart disease, high risk arrhythmias, or disease corresponding to New York Heart Association class III or IV.
Active angina or Class III or IV Congestive Heart Failure (CHF) (New York Heart Association CHF Functional Classification System) or clinically significant cardiac disease within  months of study enrollment, including myocardial infarction, unstable angina, grade  or greater peripheral vascular disease, congestive heart failure, uncontrolled hypertension, or arrhythmias not controlled by outpatient medication.
Patients with clinically significant cardiac disease (e.g. congestive heart failure New York Heart Association class III or IV, symptomatic coronary artery disease and cardiac arrhythmias not well controlled with medication), or myocardial infarction within the previous six months
Symptomatic or uncontrolled cardiovascular disease, myocardial infarction or severe/unstable angina within the past  months, or New York Heart Association class III or IV congestive heart failure
Any major cardiovascular event within  months of study initiation, including but not limited to myocardial infarction, unstable angina, cerebrovascular accident, pulmonary embolism, heart failure uncontrolled by medications or New York Heart Association class III or IV heart failure
Chronic ischemic heart disease with unstable angina, chronic heart failure at class III or IV, and myocardial infarction in the last  months
Subject has any one of the following:\r\n* Clinically significant abnormal electrocardiography (ECG) finding at screening\r\n* Congestive heart failure (New York Heart Association class III or IV)\r\n* Myocardial infarction within  months prior to starting study treatment\r\n* Unstable or poorly controlled angina pectoris, including Prinzmetal variant angina pectoris
Clinically significant heart disease (e.g., congestive heart failure of New York Heart Association class III or IV, angina not well controlled by medication, or myocardial infarction within  months)
Have the presence of cardiac disease, including a myocardial infarction within  months prior to study entry, unstable angina pectoris, New York Heart Association Class III/IV congestive heart failure, or uncontrolled hypertension.
Significant active cardiac disease within  months prior to enrollment, including but not limited to New York Heart Association class  cardiac heart failure, unstable angina, myocardial infarction
Has a history of Class II-IV congestive heart failure or myocardial infarction within  months of randomization.
